According to FutureWise analysis the market for in-vitro toxicology testing in 2023 is US$ 12.43 billion, and is expected to reach US$ 28.7 billion by 2031 at a CAGR of 11.02%.
In-vitro process is used to detect hazardous chemical substances over an isolated part of an organism. It helps in detecting the toxicity levels at early developmental stages of products like cosmetics, drugs and food additives. In-vitro toxicology involved the usage of tissues or cells that are maintained or grown in a controlled laboratory environment to examine the toxic properties of different mixtures and compounds. This testing method is primarily used for safety evaluation in drug development. It is also used for ranking chemicals based on their potency. Moreover, in-vitro toxicology testing can be used for determining dose-response, absorption, distribution, metabolism, excretion (ADME) and threshold response of drug. Depending on the technology, the market is bifurcated into cell culture technology, high throughput technology, OMICS technology and molecular imaging. Cell culture technology segment is expected to witness significant market growth during the forecast period. There have been recent advancements in the exposure of human cell culture along with test systems. This has allowed for the development and expansion of in-vitro assay systems which are demonstrative, predictive and are suitable for toxicity testing of a wide range of chemicals including airborne materials and nanomaterials. Method-wise, the market is categorised as cellular assays, biochemical assays, ex-vivo and in-silico segment.
Ex-vivo method is projected to register a noteworthy growth rate during the forecast period. This is mainly due to the increasing popularity of stem cell therapy which has encouraged scientists to implement this technique. Based on the type of application, the market is bifurcated into systemic toxicology, dermal toxicity, endocrine disruption and occular toxicity. There are different types of systemic toxicity like sub-acute systemic toxicity, acute systemic toxicity, chronic systemic toxicity and sub-chronic systemic toxicity. Such a plethora of options in one method is the primary reason for the segment to thrive.
Basis the end-use, the market is categorised as pharmaceutical industry, cosmetic and household products, diagnostics, chemical industry and food industry. The chemical industry is anticipated to showcase significant market growth due to the increase in the manufacturing of excipients for pharmaceutical and cosmetics formulations. Furthermore, the presence of a substantial product portfolio for the market will surely trigger the scope of applications of these assays in the industry. The market is regionally categorised as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific is projected to showcase significant market growth over the forecast period owing to growing research and development in pharmaceuticals coupled with consistent improvement in healthcare infrastructure. Furthermore, clinical trials are conducted at a relatively low cost than western countries. It is therefore anticipated that many globalised companies will be willing to invest massively in the Asia Pacific region.